{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:59:22Z","timestamp":1788494362461,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72274037"],"award-info":[{"award-number":["72274037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"DOI":"10.1186\/s12955-025-02383-x","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:26:40Z","timestamp":1760621200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Minimal clinically important difference of EQ-5D-5L, SF-6Dv2, and QLU-C10D in hematologic malignancy patients in China"],"prefix":"10.1186","volume":"23","author":[{"given":"Fangyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"24","key":"2383_CR1","first-page":"29","volume":"35","author":"W Gongqi","year":"2018","unstructured":"Gongqi W, Xiaoyan X, Yan H. Health-related quality of life in patients with tuberculosis who completed treatment. Nurs J Chin People\u2019s Liberation Army. 2018;35(24):29\u201333.","journal-title":"Nurs J Chin People\u2019s Liberation Army"},{"issue":"02","key":"2383_CR2","first-page":"58","volume":"38","author":"H Dong","year":"2021","unstructured":"Dong H, Tang Z, Yan X, Jiang Q. Analysis on malignant tumor treatment cost in Anhui Province\u2014\u2014Based on the SHA 2011. Health Econ Res. 2021;38(02):58\u201361.","journal-title":"Health Econ Res"},{"key":"2383_CR3","doi-asserted-by":"crossref","unstructured":"Binder AF, Brody JD. Non-Hodgkin Lymphoma. Mount Sinai Expert Guides: Oncology. 2019:342\u2013\u200953.","DOI":"10.1002\/9781119189596.ch30"},{"issue":"2","key":"2383_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.rcl.2008.03.005","volume":"46","author":"MJ Matasar","year":"2008","unstructured":"Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am. 2008;46(2):175\u201398.","journal-title":"Radiol Clin North Am"},{"issue":"24","key":"2383_CR5","first-page":"2797","volume":"128","author":"Y Mai","year":"2016","unstructured":"Mai Y, Yu JJ, Bartholdy B, Xu-Monette ZY, Knapp EE, Yuan F, et al. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. Blood. J Am Soc Hematol. 2016;128(24):2797\u2013807.","journal-title":"J Am Soc Hematol"},{"issue":"7","key":"2383_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u201391.","journal-title":"Chin Med J (Engl)"},{"key":"2383_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0686-1","volume":"12","author":"W Liu","year":"2019","unstructured":"Liu W, Liu J, Song Y, Zeng X, Wang X, Mi L, et al. Burden of lymphoma in China, 2006\u20132016: an analysis of the global burden of disease study 2016. J Hematol Oncol. 2019;12:1\u20139.","journal-title":"J Hematol Oncol"},{"issue":"02","key":"2383_CR8","first-page":"89","volume":"43","author":"ZQZJZYMLNGWQL Jie","year":"2023","unstructured":"Jie ZQZJZYMLNGWQL. Analysis of psychological elasticity and its influencing factors in patients with multiple myeloma. Harbin Med J. 2023;43(02):89\u201392.","journal-title":"Harbin Med J"},{"issue":"05","key":"2383_CR9","first-page":"855","volume":"25","author":"L Peng","year":"2018","unstructured":"Peng L. Practice guidelines for diagnosis and treatment of multiple myeloma in Zhongshan hospital,fudan University(v1.2019). Chin J Clin Med. 2018;25(05):855\u20139.","journal-title":"Chin J Clin Med"},{"issue":"21","key":"2383_CR10","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1002\/cam4.3391","volume":"9","author":"X Li","year":"2020","unstructured":"Li X, Liu J, Chen M, Gu J, Huang B, Zheng D, et al. Health-related quality of life of patients with multiple myeloma: A real-world study in China. Cancer Med. 2020;9(21):7896\u2013913.","journal-title":"Cancer Med"},{"issue":"6","key":"2383_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676\u201381.","journal-title":"Semin Oncol"},{"key":"2383_CR12","first-page":"2549","volume":"29","author":"RH Xu","year":"2021","unstructured":"Xu RH, Wong EL-y, Jin J, Huang H, Dong D. Health-related quality of life measured using EQ-5D in patients with lymphomas. Support Care Cancer. 2021;29:2549\u201360.","journal-title":"Support Care Cancer"},{"key":"2383_CR13","unstructured":"NICE U. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence (NICE) London, UK. 2013."},{"issue":"1","key":"2383_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R, Group E. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372.","journal-title":"Health Policy"},{"issue":"2","key":"2383_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M. The Estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271\u201392.","journal-title":"J Health Econ"},{"key":"2383_CR16","doi-asserted-by":"crossref","unstructured":"Janssen MF, Bonsel GJ, Luo N, Is. EQ-5D-5L better than EQ-5D-3L? A Head-to-Head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics. 2018;36(6):675\u201397.","DOI":"10.1007\/s40273-018-0623-8"},{"issue":"6","key":"2383_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40273-018-0628-3","volume":"36","author":"B Mulhern","year":"2018","unstructured":"Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, et al. Comparing the UK EQ-5D-3L and english EQ-5D-5L value sets. PharmacoEconomics. 2018;36(6):699\u2013713.","journal-title":"PharmacoEconomics"},{"issue":"09","key":"2383_CR18","first-page":"40","volume":"34","author":"YXA Ma","year":"2013","unstructured":"Ma YXA. Study on reliability and validity of Chinese version of EQ-5D-5L. Shanghai Med Pharm J. 2013;34(09):40\u20133.","journal-title":"Shanghai Med Pharm J"},{"key":"2383_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11136-015-1217-y","volume":"25","author":"M King","year":"2016","unstructured":"King M, Costa D, Aaronson N, Brazier J, Cella D, Fayers P, et al. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. Qual Life Res. 2016;25:625\u201336.","journal-title":"Qual Life Res"},{"issue":"2","key":"2383_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0163278705275340","volume":"28","author":"KJ Yost","year":"2005","unstructured":"Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28(2):172\u201391.","journal-title":"Eval Health Prof"},{"issue":"4","key":"2383_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407\u201315.","journal-title":"Control Clin Trials"},{"issue":"1","key":"2383_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/009286150303700105","volume":"37","author":"J Sloan","year":"2003","unstructured":"Sloan J, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing the clinical significance of Health-Related quality of life changes within clinical trials. Drug Inform J. 2003;37(1):23\u201331.","journal-title":"Drug Inform J"},{"issue":"5","key":"2383_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","volume":"7","author":"AG Copay","year":"2007","unstructured":"Copay AG, Subach BR, Glassman SD, Polly DW Jr., Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7(5):541\u20136.","journal-title":"Spine J"},{"key":"2383_CR24","unstructured":"Fayers PM, Machin D. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. Wiley; 2013."},{"issue":"12","key":"2383_CR25","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s11136-016-1336-0","volume":"25","author":"K Tsiplova","year":"2016","unstructured":"Tsiplova K, Pullenayegum E, Cooke T, Xie F. EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth fund survey of sicker adults in Canada. Qual Life Res. 2016;25(12):3009\u201316.","journal-title":"Qual Life Res"},{"issue":"5","key":"2383_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0895-4356(03)00044-1","volume":"56","author":"RD Crosby","year":"2003","unstructured":"Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(5):395\u2013407.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2383_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","volume":"20","author":"NS McClure","year":"2017","unstructured":"McClure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-Defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health. 2017;20(4):644\u201350.","journal-title":"Value Health"},{"issue":"2","key":"2383_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2383_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1586\/erp.11.9","volume":"11","author":"MT King","year":"2011","unstructured":"King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev PharmacoEcon Outcomes Res. 2011;11(2):171\u201384.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"2383_CR30","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77(4):371\u2013\u200983.","DOI":"10.4065\/77.4.371"},{"key":"2383_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-4-54","volume":"4","author":"HC de Vet","year":"2006","unstructured":"de Vet HC, Terwee CB, Ostelo RW, Beckerman H, Knol DL, Bouter LM. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes. 2006;4:54.","journal-title":"Health Qual Life Outcomes"},{"key":"2383_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2383_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12955-020-01578-8","volume":"18","author":"X Hu","year":"2020","unstructured":"Hu X, Jing M, Zhang M, Yang P, Yan X. Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study. Health Qual Life Outcomes. 2020;18(1):324.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"2383_CR34","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s11136-013-0593-4","volume":"23","author":"LM Sagberg","year":"2014","unstructured":"Sagberg LM, Jakola AS, Solheim O. Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference? Qual Life Res. 2014;23(5):1427\u201334.","journal-title":"Qual Life Res"},{"issue":"1","key":"2383_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12955-024-02294-3","volume":"22","author":"S Bourke","year":"2024","unstructured":"Bourke S, Bennett B, Oluboyede Y, Li T, Longworth L, O\u2019Sullivan SB, et al. Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer. Health Qual Life Outcomes. 2024;22(1):81.","journal-title":"Health Qual Life Outcomes"},{"issue":"Supplement 1","key":"2383_CR36","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/blood-2018-99-117094","volume":"132","author":"P Goswami","year":"2018","unstructured":"Goswami P, Oliva EN, Ionova T, Salek S. Responsiveness and the minimal clinically important difference for HM-PRO in patients with hematological malignancies. Blood. 2018;132(Supplement 1):2294.","journal-title":"Blood"},{"key":"2383_CR37","doi-asserted-by":"crossref","unstructured":"Breeze J, Mehta J, Tremblay G, Shacham S, Shah J, Li L et al. Pcn324 minimal clinically important difference (Mcid) for the functional assessment of Cancer Therapy - Multiple myeloma (Fact-Mm): two approaches. Value Health. 2020;23.","DOI":"10.1016\/j.jval.2020.04.1785"},{"issue":"3","key":"2383_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11136-018-2062-6","volume":"28","author":"C Quinten","year":"2019","unstructured":"Quinten C, Kenis C, Decoster L, Debruyne PR, De Groof I, Focan C, et al. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. Qual Life Res. 2019;28(3):663\u201376.","journal-title":"Qual Life Res"},{"issue":"15","key":"2383_CR39","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1080\/09638288.2023.2246013","volume":"46","author":"MKT Murao","year":"2024","unstructured":"Murao MKT, Hamada R, Miyasaka J, Matsushita M, Otagaki A, Kajimoto T, Arai Y, Kanda J, Nankaku M, Ikeguchi R, Takaori-Kondo A, Matsuda S. Minimal important difference of the 6-minute walk test after allogenic hematopoietic stem cell transplantation. Disabil Rehabil. 2024;46(15):3449\u201356.","journal-title":"Disabil Rehabil"},{"issue":"6","key":"2383_CR40","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","volume":"14","author":"SJ Walters","year":"2005","unstructured":"Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523\u201332.","journal-title":"Qual Life Res"},{"issue":"10","key":"2383_CR41","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"4","key":"2383_CR42","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s11136-012-0200-0","volume":"22","author":"N Luo","year":"2013","unstructured":"Luo N, Li M, Liu GG, Lloyd A, de Charro F, Herdman M. Developing the Chinese version of the new 5-level EQ-5D descriptive system: the response scaling approach. Qual Life Res. 2013;22(4):885\u201390.","journal-title":"Qual Life Res"},{"issue":"5","key":"2383_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/14737167.2023.2189590","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang A, Mao Z, Wang Z, Wu J, Luo N, Wang P. Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):449\u201368.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2383_CR44","doi-asserted-by":"crossref","unstructured":"Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol. 1998;51(11):1115\u201328.","DOI":"10.1016\/S0895-4356(98)00103-6"},{"key":"2383_CR45","doi-asserted-by":"crossref","unstructured":"Wu J, Xie S, He X, Chen G, Bai G, Feng D, et al. Valuation of SF-6Dv2 health States in China using time Trade-off and Discrete-Choice experiment with a duration dimension. PharmacoEconomics. 2021;39(5):521\u201335.","DOI":"10.1007\/s40273-020-00997-1"},{"key":"2383_CR46","doi-asserted-by":"crossref","unstructured":"Cao Y, Xu J, Norman R, King MT, Kemmler G, Huang W et al. Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D. Qual Life Res. 2024:1\u201315.","DOI":"10.1007\/s11136-024-03776-z"},{"key":"2383_CR47","doi-asserted-by":"crossref","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","DOI":"10.1093\/jnci\/85.5.365"},{"issue":"3","key":"2383_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s11136-021-02961-8","volume":"31","author":"J van Roij","year":"2022","unstructured":"van Roij J, Kieffer JM, van de Poll-Franse L, Husson O, Raijmakers NJH, Gelissen J. Assessing measurement invariance in the EORTC QLQ-C30. Qual Life Res. 2022;31(3):889\u2013901.","journal-title":"Qual Life Res"},{"issue":"1","key":"2383_CR49","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1186\/s12889-022-13211-y","volume":"22","author":"MJ Pilz","year":"2022","unstructured":"Pilz MJ, Gamper EM, Efficace F, Arraras JI, Nolte S, Liegl G, et al. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals. BMC Public Health. 2022;22(1):1040.","journal-title":"BMC Public Health"},{"issue":"11","key":"2383_CR50","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin\u2019s disease staging classification. Cancer Res. 1971;31(11):1860\u20131.","journal-title":"Cancer Res"},{"issue":"26","key":"2383_CR51","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2383_CR52","doi-asserted-by":"publisher","first-page":"2277503","DOI":"10.1080\/16078454.2023.2277503","volume":"28","author":"L Ren","year":"2023","unstructured":"Ren L, Ren Y, Yang Y, Wang W, Xu T, Wang Y, et al. Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National medical center in China. Hematology. 2023;28(1):2277503.","journal-title":"Hematology"},{"issue":"Suppl 1","key":"2383_CR53","doi-asserted-by":"publisher","first-page":"s122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):s122\u201350.","journal-title":"J Nucl Med"},{"issue":"9","key":"2383_CR54","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jval.2018.02.007","volume":"21","author":"NS McClure","year":"2018","unstructured":"McClure NS, Sayah FA, Ohinmaa A, Johnson JA. Minimally important difference of the EQ-5D-5L index score in adults with type 2 diabetes. Value Health. 2018;21(9):1090\u20137.","journal-title":"Value Health"},{"issue":"5","key":"2383_CR55","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582\u201392.","journal-title":"Med Care"},{"issue":"7","key":"2383_CR56","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jclinepi.2013.12.011","volume":"67","author":"YT Cheung","year":"2014","unstructured":"Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014;67(7):811\u201320.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2383_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00005650-199905000-00006","volume":"37","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999;37(5):469\u201378.","journal-title":"Med Care"},{"issue":"9","key":"2383_CR58","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","volume":"52","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52(9):861\u201373.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2383_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MLR.0b013e3181c162a2","volume":"48","author":"N Luo","year":"2010","unstructured":"Luo N, Johnson J, Coons SJ. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care. 2010;48(4):365\u201371.","journal-title":"Med Care"},{"issue":"8","key":"2383_CR60","doi-asserted-by":"publisher","first-page":"e3053","DOI":"10.1002\/dmrr.3053","volume":"34","author":"X Jin","year":"2018","unstructured":"Jin X, Liu GG, Gerstein HC, Levine MAH, Guan H, Li H, et al. Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China. Diabetes Metab Res Rev. 2018;34(8):e3053.","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"2383_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/ejh.14035","volume":"111","author":"R Burstein","year":"2023","unstructured":"Burstein R, Aviv A, Even-Zohar NG, Nachmias B, Haran A, Braun M, et al. Comparing end-of-life care of hematologic malignancy versus solid tumor patients in a tertiary care center. Eur J Haematol. 2023;111(4):528\u201335.","journal-title":"Eur J Haematol"},{"issue":"1","key":"2383_CR62","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jpainsymman.2017.08.030","volume":"55","author":"MJ Hochman","year":"2018","unstructured":"Hochman MJ, Yu Y, Wolf SP, Samsa GP, Kamal AH, LeBlanc TW. Comparing the palliative care needs of patients with hematologic and solid malignancies. J Pain Symptom Manage. 2018;55(1):82\u20138. e1.","journal-title":"J Pain Symptom Manage"},{"key":"2383_CR63","doi-asserted-by":"publisher","first-page":"111487","DOI":"10.1016\/j.jclinepi.2024.111487","volume":"174","author":"LJ Cheng","year":"2024","unstructured":"Cheng LJ, Chen LA, Cheng JY, Herdman M, Luo N. Systematic review reveals that EQ-5D minimally important differences vary with treatment type and May decrease with increasing baseline score. J Clin Epidemiol. 2024;174:111487.","journal-title":"J Clin Epidemiol"},{"key":"2383_CR64","first-page":"e20233449","volume":"46","author":"F Cosci","year":"2024","unstructured":"Cosci F, Christensen KS, Ceccatelli S, Patierno C, Carrozzino D. Patient health Questionnaire-9: A clinimetric analysis. Braz J Psychiatry. 2024;46:e20233449.","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"2383_CR65","doi-asserted-by":"publisher","first-page":"e70022","DOI":"10.1002\/cpp.70022","volume":"31","author":"F Cosci","year":"2024","unstructured":"Cosci F, Carrozzino D, Patierno C, Romanazzo S, Berrocal C, Chiarugi A, et al. Mental pain questionnaire: clinimetric properties of a potential global Person-Centred outcome measure. Clin Psychol Psychother. 2024;31(6):e70022.","journal-title":"Clin Psychol Psychother"},{"issue":"3","key":"2383_CR66","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/str0000280","volume":"30","author":"D Carrozzino","year":"2023","unstructured":"Carrozzino D, Patierno C, Pignolo C, Christensen KS. The concept of psychological distress and its assessment: A clinimetric analysis of the SCL-90-R. Int J Stress Manage. 2023;30(3):235\u201348.","journal-title":"Int J Stress Manage"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-025-02383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-025-02383-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-025-02383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:05:48Z","timestamp":1760627148000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-025-02383-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1186\/s12955-025-02383-x","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the final manuscript and consented to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}